BTC $64,798.57 +1.02%
ETH $1,812.86 +0.87%
BNB $592.74 +0.71%
XRP $0.9676 +1.60%
SOL $73.26 +3.16%
TRX $0.3055 +0.19%
DOGE $0.0591 +0.90%
ADA $0.1540 +1.57%
BCH $210.50 +2.72%
LINK $9.24 +1.24%
HYPE $69.11 +4.93%
AAVE $113.57 +4.36%
SUI $0.7326 +1.98%
XLM $0.1396 +1.14%
ZEC $945.00 +7.26%
AAPL $352.02 -1.85%
AMZN $259.69 -2.06%
GOOGL $284.47 -3.40%
MSFT $517.16 -1.63%
META $624.96 -1.86%
NVDA $157.51 +0.29%
TSLA $381.96 -1.15%
SNDK $826.48 -0.04%
INTC $55.11 -2.77%
SPCX $139.43 -0.21%
MU $733.32 -0.83%
AMD $516.07 +1.72%
BTC $64,798.57 +1.02%
ETH $1,812.86 +0.87%
BNB $592.74 +0.71%
XRP $0.9676 +1.60%
SOL $73.26 +3.16%
TRX $0.3055 +0.19%
DOGE $0.0591 +0.90%
ADA $0.1540 +1.57%
BCH $210.50 +2.72%
LINK $9.24 +1.24%
HYPE $69.11 +4.93%
AAVE $113.57 +4.36%
SUI $0.7326 +1.98%
XLM $0.1396 +1.14%
ZEC $945.00 +7.26%
AAPL $352.02 -1.85%
AMZN $259.69 -2.06%
GOOGL $284.47 -3.40%
MSFT $517.16 -1.63%
META $624.96 -1.86%
NVDA $157.51 +0.29%
TSLA $381.96 -1.15%
SNDK $826.48 -0.04%
INTC $55.11 -2.77%
SPCX $139.43 -0.21%
MU $733.32 -0.83%
AMD $516.07 +1.72%

acquires

All
Article
Flash

first_img Cognition acquires AI coding security company Corridor

On October 28, Jack Cable, co-founder of AI coding security company Corridor, and Ashwin Ramaswami published an article on the Cognition official website stating that Corridor will join Cognition and take Devin Security to the next stage. Cognition later stated on X that the company is acquiring Corridor. Cognition is the developer of AI software engineer Devin.Jack Cable and Ashwin Ramaswami wrote that Corridor was founded about two years ago with the mission of accelerating secure and autonomous software development, and it has now become a security layer for AI-native teams. The two stated that they will collaborate with Cognition President and early Corridor advisor Russell Kaplan, Chief Security Officer Alex Stamos, and Chief Technology Officer Steven Hao. They also mentioned that throughout their careers, they have discovered and fixed vulnerabilities in critical systems and believe that AI agents are now capable of executing end-to-end attack chains, necessitating new tools for defenders.Previously, Corridor announced in August 2025 the completion of a $5.4 million seed round led by Conviction, and in March 2026 announced the completion of a $25 million Series A round led by Felicis, with a valuation of $200 million, with participation from Conviction, Timeless, Lux Capital, Datadog, SV Angel, and others. Its product positioning is to embed security controls in the process of AI-generated code, rather than adding security measures after the code is written.

first_img OpenAI acquires Orchestra Bio, AI entities take over drug development

OpenAI announced the acquisition of San Francisco startup Orchestra Bio, which has developed AI agents to help pharmaceutical companies track the progress of drug development projects. Orchestra's team and platform will be integrated into OpenAI's life sciences product line Rosalind, aimed at biologists and chemists, with the transaction amount undisclosed. Orchestra was founded in the fall of 2022, with seed funding from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, raising a total of approximately $20 million.According to OpenAI, a new drug can take up to 15 years from initial conception to approval in the United States, and the cost of bringing a single approved drug to market can exceed $2.6 billion, with less than 10% of candidate drugs entering human trials ultimately reaching the market. Orchestra's AI agents can automatically monitor tasks and flag issues, analyze how setbacks like production batch failures affect the overall development project, compile relevant information, and compare response strategies, ultimately allowing scientists and project leaders to make decisions.This acquisition follows competitor Anthropic's acquisition of Coefficient Bio for approximately $400 million in April, reflecting the competition among AI labs for new drug development workflows. In April, OpenAI launched the model GPT-Rosalind specifically designed for biology and drug discovery, available only to vetted U.S. corporate clients such as Amgen and Moderna, with the accompanying product Rosalind Workbench connecting the model to research tools and data.
app_icon
ChainCatcher Building the Web3 world with innovations.